Stockreport

Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer

Verastem, Inc.  (VSTM) 
Last verastem, inc. earnings: 10/29 04:17 pm Check Earnings Report
US:NASDAQ Investor Relations: verastem.com
PDF No dose-limiting toxicities were observed in the RAMP 203 first triplet combination cohort of avutometinib and LUMAKRAS™ (sotorasib) plus defactinib in patients previous [Read more]